Therapeutic Programs Under Development

Sangamo’s robust and diverse pipeline of genomic medicines in clinical and preclinical stages of development encompass a breadth of distinct but complementary technical approaches. We are developing capabilities that allow us to design therapeutic approaches to resolve the underlying genetic causes of disease, using whichever technology is best suited to deliver that treatment. We prioritize research targets and clinical candidates where there is high unmet patient need, where the disease biology is understood, and where our suite of technologies has the potential to make a difference.

Our pipeline comprises a balance of wholly owned and partnered programs. We collaborate with partners when additional resources and therapeutic area expertise may help us bring our medicines to patients more quickly.

Preclinical

img:Icon
PKU
(ST-101)
SANGAMO WHOLLY OWNED
img:Icon
IBD
SANGAMO WHOLLY OWNED
img:Icon
MS
SANGAMO WHOLLY OWNED
img:Icon
Oncology
PARTNERimg:logo
img:Icon
Oncology
(Kite-037)
PARTNERimg:logo
img:Icon
ALS/FTD
PARTNERimg:logo
img:Icon
Huntington’s Disease
(TAK-686)
PARTNERimg:logo
img:Icon
α-Synuclein
(ST-502)
PARTNERimg:logo
img:Icon
Tauopathies
(ST-501)
PARTNERimg:logo
img:Icon
Neurological
PARTNERimg:logo
img:Icon
Prion
SANGAMO WHOLLY OWNED
img:Icon
Neurodevelopmental Disorders
PARTNERimg:logo

Phase 1/2

img:Icon
Fabry Disease
(ST-920)
SANGAMO WHOLLY OWNED
img:Icon
Renal Transplant
(TX200)
SANGAMO WHOLLY OWNED
img:Icon
Sickle Cell Disease
(SAR445136)
PARTNERimg:logo
img:Icon
Beta Thalassemia
(ST-400)
PARTNERimg:logo

Phase 3

img:Icon
Hemophilia A
(SB-525 /
giroctocogene fitelparvovec)
PARTNERimg:logo
  • img:Icon Gene Therapy
  • img:Icon Ex Vivo
    Gene-Edited Cell Therapy
  • img:Icon In Vivo
    Genome Editing
  • img:Icon In Vivo
    Genome Regulation